Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 12/20 | 0.76 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.76 |
| ▸ | KDR | P35968 | 4/20 | 0.76 |
| ▸ | FLT1 | P17948 | 2/20 | 0.76 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.76 |
| ▸ | RET | P07949 | 4/20 | 0.71 |
| ▸ | FLT3 | P36888 | 3/20 | 0.71 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.71 |
| ▸ | TLK2 | Q86UE8 | 6/20 | 0.68 |
| ▸ | JAK3 | P52333 | 4/20 | 0.68 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.68 |
| ▸ | SYK | P43405 | 1/20 | 0.68 |
| ▸ | ATM | Q13315 | 1/20 | 0.68 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.68 |
| ▸ | AURKA | O14965 | 1/20 | 0.68 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.68 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.68 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.68 |
| ▸ | LCK | P06239 | 1/20 | 0.68 |
| ▸ | FYN | P06241 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5728408 | 1.00 | PDPK1 (0.76) | PDPK1PDGFRBKDRFLT1PDGFRA | |
| SCHEMBL396431 | 0.89 | PDGFRB (0.71) | PDPK1PDGFRBKDRFLT1PDGFRA | |
| SCHEMBL396432 | 0.89 | PDGFRB (0.71) | PDPK1PDGFRBKDRFLT1PDGFRA | |
| SCHEMBL19691 | 0.86 | PDPK1 (1.00) | PDPK1PDGFRBKDRFLT1PDGFRA | |
| SCHEMBL19692 | 0.86 | PDPK1 (1.00) | PDPK1PDGFRBKDRFLT1PDGFRA | |
| SCHEMBL3912682 | 0.83 | PDGFRB (1.00) | PDPK1PDGFRBKDRFLT1PDGFRA | |
| SCHEMBL5727973 | 0.83 | PDPK1 (1.00) | PDPK1PDGFRBKDRFLT1PDGFRA | |
| SCHEMBL5373346 | 0.83 | PDPK1 (0.71) | PDPK1PDGFRBKDRFLT1PDGFRA | |
| SCHEMBL13081202 | 0.83 | PDGFRB (0.80) | PDPK1PDGFRBKDRFLT1PDGFRA | |
| SCHEMBL18054 | 0.83 | PDPK1 (1.00) | PDPK1PDGFRBKDRFLT1PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1680401-A2 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | Schering Aktiengesellschaft (DE) | 2006-07-19 | — | — | EP | claimed |
| WO-2005040116-A2 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-06 | — | — | WO | claimed |
| US-20050090541-A1 | Indolinone derivatives and their use in treating disease-states such as cancer | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-04-28 | — | — | US | claimed |
| US-20170240522-A1 | BENZOTHIOPHENE, BENZYLOXYBENZYLIDENE AND INDOLINE DERIVATIVES USEFUL FOR THE TREATMENT OF TUBERCULOSIS | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (CH) | 2017-08-24 | — | — | US | disclosed |
| WO-2016041972-A1 | BENZOTHIOPHENE, BENZYLOXYBENZYLIDENE AND INDOLINE DERIVATIVES USEFUL FOR THE TREATMENT OF TUBERCULOSIS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2016-03-24 | — | — | WO | disclosed |
| WO-2012025726-A1 | Novel Hybrid Compounds | UNIVERSITY OF GREENWICH (GB) | 2012-03-01 | — | — | WO | disclosed |
| US-20100298376-A1 | USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-11-25 | — | — | US | disclosed |
| US-7105563-B2 | Indolinone derivatives and their use in treating disease-states such as cancer | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-09-12 | — | — | US | disclosed |
| EP-1680401-A2 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | Schering Aktiengesellschaft (DE) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005040116-A2 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-06 | — | — | WO | disclosed |
| US-20050090541-A1 | Indolinone derivatives and their use in treating disease-states such as cancer | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-04-28 | — | — | US | disclosed |
| US-20030199511-A1 | Kinase inhibitors | ABBVIE INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | disclosed |
| US-20030162785-A1 | Protein kinase inhibitors | ABBVIE INC. | 2003-08-28 | — | — | US | disclosed |
| WO-2003051366-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ABBOTT LABORATORIES (US) | 2003-06-26 | — | — | WO | disclosed |
| US-20030119839-A1 | Protein kinase inhibitors | ABBOTT LABORATORIES | 2003-06-26 | — | — | US | disclosed |
| CN-1331689-A | 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles | HOFFMANN LA ROCHE (CH) | 2002-01-16 | — | — | CN | disclosed |
| US-6313310-B1 | JUN N-TERMINAL KINASE (JNK) ENZYME INHIBITORS; ANTIINFLAMMATORY AGENTS; RHEUMATIC ARTHRITIS AND NEURO-DEGENERATIVE DISEASE TREATMENT | HOFFMANN-LA ROCHE INC. | 2001-11-06 | — | — | US | disclosed |
| EP-1149092-A2 | 4- AND 5-ALKYNYLOXINDOLES AND 4- AND 5-ALKENYLOXINDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-31 | — | — | EP | disclosed |
| WO-2000035906-A2 | 4- AND 5-ALKYNYLOXINDOLES AND 4- AND 5-ALKENYLOXINDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187026-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | PDPK1 84/4885PDGFRB 1016/4885KDR 1817/4885 |
| US-20100298376-A1 | USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | NLN, HTT, PARK7 | PDPK1 438/4885PDGFRB 2159/4885KDR 3586/4885 |
| US-20030199511-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | PDPK1 84/4885PDGFRB 1016/4885KDR 1817/4885 |
| US-20030162785-A1 | Protein kinase inhibitors | MAP3K20, MAP3K1, MAP3K6 | PDPK1 90/4885PDGFRB 766/4885KDR 1241/4885 |
| US-20050090541-A1 | Indolinone derivatives and their use in treating disease-states such as cancer | PDK3, PDK2, PDK4 | PDPK1 4/4885PDGFRB 1462/4885KDR 2521/4885 |
| US-20030119839-A1 | Protein kinase inhibitors | MAP3K20, MAP3K1, MAP3K6 | PDPK1 90/4885PDGFRB 766/4885KDR 1241/4885 |
| US-20170240522-A1 | BENZOTHIOPHENE, BENZYLOXYBENZYLIDENE AND INDOLINE DERIVATIVES USEFUL FOR THE TREATMENT OF TUBERCULOSIS | INMT, IDO2, IDO1 | PDPK1 1142/4885PDGFRB 2274/4885KDR 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.